據報內地監管部門明確北交所股票屬國內依法發行上市交易股票
據《中國證券報》從監管部門獲悉,日前監管部門已通過派出機構向基金管理人和託管人下發通知,明確北交所股票屬於國內依法發行上市交易的股票,公募基金可按照合同約定進行投資。公募基金參與新三板投資仍參考早前相關指引執行。
有業內人士表示,此舉明確了公募基金投資北交所股票的口徑。根據基金法,公募基金可以投資國內依法發行上市的股票,而在北交所交易股票即屬於公開發行上市股票。明確「公募基金參與新三板投資仍參考此前相關指引執行」,意味着過渡期內公募基金不可以隨意投資精選層股票,過渡期內公募基金投資精選層股票還是要根據《公開募集證券投資基金投資全國中小企業股份轉讓系統掛牌股票指引》執行。(ta/w) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.